Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8WGT

Crystal structure of V30M-TTR in complex with compound 7

Summary for 8WGT
Entry DOI10.2210/pdb8wgt/pdb
DescriptorTransthyretin, [4,7-bis(chloranyl)-2-ethyl-1-benzofuran-3-yl]-[3,5-bis(iodanyl)-4-oxidanyl-phenyl]methanone (3 entities in total)
Functional Keywordstransthyretin, amyloidosis, inhibitor, benziodarone derivative, transport protein
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight35859.11
Authors
Yokoyama, T. (deposition date: 2023-09-22, release date: 2024-05-15, Last modification date: 2024-05-29)
Primary citationMizuguchi, M.,Nakagawa, Y.,Yokoyama, T.,Okada, T.,Fujii, K.,Takahashi, K.,Luan, N.N.T.,Nabeshima, Y.,Kanamitsu, K.,Nakagawa, S.,Yamakawa, S.,Ueda, M.,Ando, Y.,Toyooka, N.
Development of Benziodarone Analogues with Enhanced Potency for Selective Binding to Transthyretin in Human Plasma.
J.Med.Chem., 67:6987-7005, 2024
Cited by
PubMed Abstract: Transthyretin amyloidosis is a fatal disorder caused by transthyretin amyloid aggregation. Stabilizing the native structure of transthyretin is an effective approach to inhibit amyloid aggregation. To develop kinetic stabilizers of transthyretin, it is crucial to explore compounds that selectively bind to transthyretin in plasma. Our recent findings demonstrated that the uricosuric agent benziodarone selectively binds to transthyretin in plasma. Here, we report the development of benziodarone analogues with enhanced potency for selective binding to transthyretin in plasma compared to benziodarone. These analogues featured substituents of chlorine, bromine, iodine, a methyl group, or a trifluoromethyl group, at the 4-position of the benzofuran ring. X-ray crystal structure analysis revealed that CH···O hydrogen bonds and a halogen bond are important for the binding of the compounds to the thyroxine-binding sites. The bioavailability of benziodarone analogues with 4-Br, 4-Cl, or 4-CH was comparable to that of tafamidis, a current therapeutic agent for transthyretin amyloidosis.
PubMed: 38670538
DOI: 10.1021/acs.jmedchem.3c02286
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.696 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon